Stay updated on ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Sign up to get notified when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.

Latest updates to the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedNew study sites were added across Belgium, Canada, Czechia, Hungary, Poland, Spain, and other regions. Several previously listed locations were removed, and the page revision updated to v3.3.3.SummaryDifference1%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; a minor metadata banner change that does not affect content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page no longer displays a notice about government-funding/operational status. This previously advised that information may be out of date and linked to status updates.SummaryDifference0.3%

- Check60 days agoChange DetectedThe new page shows minor formatting tweaks and small text edits without altering core study information such as eligibility criteria, interventions, outcomes, or listed locations.SummaryDifference0.3%

- Check88 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

Stay in the know with updates to ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.